American Journal of Clinical Dermatology

, Volume 10, Issue 3, pp 205–210 | Cite as

67th annual Meeting of the American Academy of Dermatology

San Francisco, California, USA, 6–10 March 2009
  • Kathy Fraser
Meeting Report 67th Annual Meeting of the American Academy of Dermatology


This year’s annual meeting of the American Academy of Dermatology was attended by over 18 500 international delegates, and featured presentations from world-renowned leaders in the field of dermatology, including research in the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails.


Psoriasis Acne Hemangioma Tumor Necrosis Factor Inhibitor Actinic Keratosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (6): 580–92PubMedCrossRefGoogle Scholar
  2. 2.
    Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625): 1675–84PubMedCrossRefGoogle Scholar
  3. 3.
    Griffiths C, Menter A, Strober B, et al. A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis [poster no. 3318]. J Am Acad Dermatol 2009; 60 (3): AB166Google Scholar
  4. 4.
    Kimball AB, Gordon KB, Langley RG, et al., ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144 (2): 200–7Google Scholar
  5. 5.
    Kimball A, Zhong J, Valdes J, et al. Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial [poster no. 3326]. J Am Acad Dermatol 2009; 60 (3): AB168Google Scholar
  6. 6.
    Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008; 118 (9): 3151–9PubMedCrossRefGoogle Scholar
  7. 7.
    Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral antiinflammatory agent, apremilast. Curr Med Res Opin 2008; 24 (5): 1529–38PubMedCrossRefGoogle Scholar
  8. 8.
    Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008; 371 (9621): 1337–42PubMedCrossRefGoogle Scholar
  9. 9.
    Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6 (4): 428–35PubMedGoogle Scholar
  10. 10.
    Gottschalk RW, Johnson LA. Calcitriol 3 micrograms/g versus calcipotriol 50 micrograms/g for plaque psoriasis: treatment, maintenance and cost [poster no. 2720]. J Am Acad Dermatol 2007; AB179Google Scholar
  11. 11.
    Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg/g ointment and calcipotriol 50 microg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003; 148 (2): 326–33PubMedCrossRefGoogle Scholar
  12. 12.
    Paller AS, Siegfried EC, Langley RG, et al., Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358 (3): 241–51Google Scholar
  13. 13.
    Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66 (5): 670–5PubMedCrossRefGoogle Scholar
  14. 14.
    Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (7): 1213–8PubMedGoogle Scholar
  15. 15.
    Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infection presenting as a periumbilical folliculitis. Cutis 2006; 77 (4): 229–32PubMedGoogle Scholar
  16. 16.
    Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007; 67 (10): 1483–512PubMedCrossRefGoogle Scholar
  17. 17.
    Zhanel GG, Lam A, Schweizer F, et al. Ceftobiprole: a review of a broadspectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9 (4): 245–54PubMedCrossRefGoogle Scholar
  18. 18.
    Yang LPH, Kearn SJ. Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections. Am J Clin Dermatol 2008; 9 (6): 411–3PubMedCrossRefGoogle Scholar
  19. 19.
    Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59 (5): 792–800PubMedCrossRefGoogle Scholar
  20. 20.
    Draelos ZD, Carter E, Maloney JM, et al., United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56 (3): 439. e1-10Google Scholar
  21. 21.
    Thiboutot DM, Weiss J, Bucko A, et al., Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57 (5): 791–9Google Scholar
  22. 22.
    Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4 (12): 813–31Google Scholar
  23. 23.
    Alexiades-Armenakas M. Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild to severe comedonal, inflammatory, or cystic acne. J Drugs Dermatol 2006; 5 (1): 45–55PubMedGoogle Scholar
  24. 24.
    Moloney FJ, Collins P. Randomized double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157 (1): 87–91PubMedCrossRefGoogle Scholar
  25. 25.
    Szeimies R-M, Bichel J, Ortonne J-P, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008; 159 (1): 205–10PubMedCrossRefGoogle Scholar
  26. 26.
    Dudek AZ, Mescher MF, Okazaki I, et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol 2008; 31 (2): 173–81PubMedCrossRefGoogle Scholar
  27. 27.
    Testori A, Richards J, Whitman E, et al., C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. Clin Oncol 2008; 26 (6): 955–62Google Scholar
  28. 28.
    Léauté-Labrèze C, Dumas de La Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24): 2649–51PubMedCrossRefGoogle Scholar
  29. 29.
    Bonifazi E, Colonna V, Mazzotta F, et al. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol 2008; 18 (3): 185–92Google Scholar
  30. 30.
    Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy [letter]. N Engl J Med 2008; 359 (26): 2846; author reply 2846-7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Kathy Fraser
    • 1
  1. 1.Wolters Kluwer Health / AdisAucklandNew Zealand

Personalised recommendations